Quantcast

Latest Neuroendocrine tumor Stories

2014-09-09 12:26:46

Clinical Trials Will Continue to Play a Key Role in this Growing Market, According to Findings from Decision Resources Group BURLINGTON, Mass., Sept. 9, 2014 /PRNewswire/ -- Decision Resources Group finds that the United States interventional oncology device market will see strong growth, reaching a value of $760 million by 2023. Rising cancer incidence rates combined with the ineffectiveness of chemotherapy and demand for less invasive procedures will support interventional oncology device...

2014-07-15 23:14:44

Targeted therapy for pancreatic cancer is based on personalized medicine approach Somerville, Massachusetts (PRWEB) July 15, 2014 ANDARIX Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for cancer announced today that Tozaride, the Company's lead candidate, has been granted Orphan Drug Designation by the U.S. Food & Drug Administration (FDA) for the treatment of pancreatic cancer. Pancreatic cancer is responsible for significant cancer...

2014-03-24 23:27:51

Lead Candidate Provides Targeted and Personalized Medicine Approach to Lung Cancer Somerville, MA (PRWEB) March 24, 2014 ANDARIX Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for lung and neuroendocrine cancer announced today that P2045, the Company's lead candidate for targeted peptide therapy, has been granted Orphan Drug Designation by the U.S. Food & Drug Administration (FDA) for the treatment of small cell lung cancer (SCLC). Orphan...

2014-03-04 08:31:27

SAINT-GENIS-POUILLY, France, March 4, 2014 /PRNewswire/ -- Advanced Accelerator Applications (AAA), a fast growing international player in Molecular Nuclear Medicine (MNM), announced today that they have received orphan drug designation status for their radiopharmaceutical, Gallium-68 DOTATATE. The orphan drug designation has been granted by both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for use of Gallium-68 DOTATATE as a diagnostic...

2014-02-21 23:03:28

BerriHealth continues to support research for the neuroendocrine tumor and carcinoid cancer community. Portland, Oregon (PRWEB) February 21, 2014 BerriHealth, a leader in providing high-quality black raspberry powder for clinical trials and directly to consumers online, has donated a portion of their 2013 sales to New Orleans Louisiana Neuroendocrine Tumor Specialists (NOLANETS), led by Dr. Eugene Woltering. The program is a collaborative effort between the Louisiana State University...

2014-02-14 23:04:29

From Patient to Survivor: Author’s Medical Background and Own Cancer Experience Provides Insight and Inspiration for Rare Type of Cancer San Francisco (PRWEB) February 14, 2014 Over 90% of all carcinoid and neuroendocrine tumors are incorrectly diagnosed and treated for the wrong disease. Maria Gonzalez, MSN, FNP/PA-C, hopes to help reverse this trend by increasing the awareness of this rare and poorly understood type of cancer. Her new book, “But You Look So Good… Stories by...

2014-01-29 16:29:03

DUBLIN, January 29, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/q8l6jf/lexicons) has announced the addition of the "Lexicon's telotristat - A new approach to carcinoid syndrome" [http://www.researchandmarkets.com/research/q8l6jf/lexicons ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Lexicon is developing telotristat as therapy for carcinoid syndrome, an orphan' disease that occurs...

2014-01-16 16:24:37

Research uncovers clinically actionable biomarker targets and key treatment insights for colorectal, gastric, neuroendocrine and appendiceal cancer patients IRVING, Texas, Jan. 16, 2014 /PRNewswire/ -- Caris Life Sciences®, a leading biosciences company focused on fulfilling the promise of personalized medicine, will present multiple tumor profiling studies at the 2014 Gastrointestinal Cancers Symposium held this week in San Francisco, Calif. This research demonstrates the impact of Caris...

2014-01-05 23:03:02

RadioMedix, Inc. is proud to announce that the company has received approval of “Orphan Drug Designation” for 68Ga-DOTATATE (GalioMedix ™) as a diagnostic agent for the management of patients with neuroendocrine tumors (NETs) by U.S Food and Drug Administration (FDA). Houston, TX (PRWEB) January 05, 2014 RadioMedix, Inc. is proud to announce that the company has received approval of “Orphan Drug Designation” for 68Ga-DOTATATE (GalioMedix ™) as a diagnostic agent for the...

2013-12-11 13:21:25

Chinese researchers from Rui-Jin Hospital, Shanghai Jiao-Tong University School of Medicine, BGI and other institutes identified the recurrent T372R mutation in the transcription factor YY1 (Yin Yang 1) are related with insulinoma oncogenesis, implicating a potential marker for the diagnosis and treatment of functional pancreatic neuroendocrine tumors (PNETs). The latest study was published online in Nature Communications. Pancreatic neuroendocrine tumors are classified into functional and...


Word of the Day
vermicular
  • Like a worm in form or movement; vermiform; tortuous or sinuous; also, writhing or wriggling.
  • Like the track or trace of a worm; appearing as if worm-eaten; vermiculate.
  • Marked with fine, close-set, wavy or tortuous lines of color; vermiculated.
  • A form of rusticated masonry which is so wrought as to appear thickly indented with worm-tracks.
This word ultimately comes from the Latin 'vermis,' worm.
Related